Allergenic proteins and peptides from Japanese cedar pollen

US6982326B1 · kind B1 · utility

Assignee

• ImmuLogic Pharmaceutical Corporation · US

Inventors

• Irwin J. Griffith · North Reading, US
• Joanne Pollock · Arlington, US
• Julian F. Bond · Weymouth, US
• Richard D. Garman · Arlington, US
• Mei-chang Kuo · Palo Alto, US
• Stephen P. Powers · Waltham, US
• Mark A. Exley · Sharon, US
• Xian Chen · North Chelmsford, US
• Ze'ev Shaked · Berkeley, US

Key dates

• Filing date: Jan 29, 1999
• Grant date: Jan 3, 2006
• Expiry date: Sep 23, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K39/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides nucleic acid sequences coding for the Cryptomeria japonica major pollen allergen Cry j I, Cry j II, Jun s I and Jun v I and fragments or peptides thereof. The present invention also provides purified Cry j I, Cry j II, Jun s I and Jun v I and at least one fragment thereof produced in a host cell transformed with a nucleic acid sequence coding for Cry j I, Cry j II, Jun s I and Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I or at least one fragment thereof, and fragments of Cry j I, Cry j II, Jun s I or Jun v I prepared synthetically. Cry j I, Cry j II, Jun s I and Jun v I and fragments thereof are useful for diagnosing, treating, and preventing Japanese cedar pollinosis. The present invention also provides isolated peptides of Cry j I and Cry j II. Peptides within the scope of the invention comprise at least one T cell epitope, or preferably at least two T cell epitopes of Cry j I or Cry j II. The invention also pertains to modified peptides having similar or enhanced therapeutic properties as the corresponding naturally-occurring allergen or portion thereof but having reduced side effects. Methods of …